Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02834780 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
A Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, sponsored by H3 Biomedicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
- 20
- Study locations
NCT02834780 is a Phase 1 study of Hepatocellular Carcinoma and Liver Cancer that has completed, run by H3 Biomedicine. The registered enrollment target is 128 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT02834780, a Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, has completed, sponsored by H3 Biomedicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
Conditions Studied
Interventions
- DRUG H3B-6527
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- UC Irvine Medical Center - Orange
- UCLA Medical Center - Santa Monica
Texas
- Simmons Comprehensive Cancer Center - Dallas
- University of Texas Southwestern Medical Center - Dallas
Other
- Universitair Ziekenhuis Gent - Ghent
- Institut Bergonié - Bordeaux
District of Columbia
- Georgetown Unversity Lombardi Comprehensive Cancer Center - Washington D.C.
Illinois
- Northwestern Unversity - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
New Jersey
- John theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2016-12-28 |
| Est. Completion | 2022-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02834780
The ClinicalTrials.gov registry entry for NCT02834780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (50% lower). The listed sponsor is H3 Biomedicine, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which H3B-6527 is the first listed.
NCT02834780 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT02834780 about?
NCT02834780 is a clinical study titled "Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma". The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
What is the current status of trial NCT02834780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2016-12-28. Estimated completion is 2022-02-23.
What conditions does trial NCT02834780 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Advanced Hepatocellular Carcinoma, Liver Neoplasms, Hepatic Cancer.
What interventions are being tested in trial NCT02834780?
The interventions under investigation include: H3B-6527 (DRUG).
Who is sponsoring clinical trial NCT02834780?
This trial is sponsored by H3 Biomedicine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02834780 being conducted?
This trial has 20 study locations across California, District of Columbia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.